Document Detail


Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome.
MedLine Citation:
PMID:  19286628     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Repair mechanisms resulting in alveolar protein degradation in acute respiratory distress syndrome (ARDS) are largely unknown. OBJECTIVES: To test whether the 20S proteasome is present and functional in the alveolar space in patients with ARDS. METHODS: Proteasome antigenic concentration in bronchoalveolar lavage (BAL) supernatants was measured by ELISA in patients with ARDS (n = 64), acute lung injury (ALI) (n = 8), sarcoidosis (n = 13), and in healthy subjects (n = 8). Cleavage of specific fluorogenic substrates (+/-epoxomicin), I(125) albumin degradation rate, and gel filtration were used to quantify and characterize proteasomal activity. The presence of proteasomes was confirmed independently by electron microscopic techniques. MEASUREMENTS AND MAIN RESULTS: Proteasome concentrations in patients with ARDS were markedly increased (1,069 +/- 1,194 ng/ml) in comparison to healthy subjects (60.8 +/- 49.8; P < 0.001), ALI (154 +/- 43; P = 0.006), and sarcoidosis (97.6 +/- 42.2; P = 0.037). All fluorogenic substrates were hydrolyzed (Suc-LLVY-AMC, 3.6 +/- 8.8 pkat/mg; BZ-VGR-AMC, 1.8 +/- 3.1; Suc-LLE-AMC, 1 +/- 1.7) by BAL supernatants of patients with ARDS, with inhibition by epoxomicin (P = 0.0001), and the majority of proteolytic activity was detected in BAL supernatant. Maximum hydrolyzing activity occurred at 660 kD and 20S proteasome was seen microscopically after purification and being released by pneumocytes type II. Proteasomal activity and albumin degradation rate in patients with ARDS were approximately 17-fold lower than in healthy subjects. Proteasomal activity in normal BAL was inhibited by BAL aliquots from patients with ARDS but not by denatured BAL, and returned to normal by purification. CONCLUSIONS: For the first time, we identified extracellular, biologically active 20S proteasome in the alveolar space of patients with ARDS in concentrations much higher than in normal subjects or in those with ALI.
Authors:
Stephan Urs Sixt; Michael Adamzik; Daniel Spyrka; Boris Saul; Jan Hakenbeck; Jeremias Wohlschlaeger; Ulrich Costabel; Alexander Kloss; Jan Giesebrecht; Burkhardt Dahlmann; Jürgen Peters
Related Documents :
8563098 - Autonomic nervous disorder in motor neuron disease: a study of advanced stage patients.
12232458 - Weaning from mechanical ventilation by long-term nasal positive pressure ventilation in...
3743148 - Clinical outcome of respiratory failure in patients requiring prolonged (greater than 2...
6728668 - Pyometra in the dog--a pathophysiological investigation. vi: acid-base status and serum...
10695418 - Assessment of malnutrition in alcoholic and non alcoholic cirrhotics.
2805608 - Lung function in essential mixed cryoglobulinemia: a short-term follow-up.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2009-03-12
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  179     ISSN:  1535-4970     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-05     Completed Date:  2009-06-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1098-106     Citation Subset:  AIM; IM    
Affiliation:
Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Hufelandstrasse 55, Essen, Germany. anaesthesixt@gmx.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Biological Markers / metabolism
Bronchoalveolar Lavage Fluid / chemistry
Disease Progression
Enzyme-Linked Immunosorbent Assay
Extracellular Fluid / enzymology*
Female
Follow-Up Studies
Germany
Humans
Incidence
Male
Microscopy, Immunoelectron
Middle Aged
Prognosis
Prospective Studies
Proteasome Endopeptidase Complex / metabolism*
Pulmonary Alveoli / enzymology*,  ultrastructure
Respiratory Distress Syndrome, Adult / enzymology*,  epidemiology,  pathology
Risk Factors
Chemical
Reg. No./Substance:
0/Biological Markers; EC 3.4.25.1/Proteasome Endopeptidase Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Baroreflex gain in children with obstructive sleep apnea.
Next Document:  An expanded seed sequence definition accounts for full regulation of the hid 3' UTR by bantam miRNA.